If you searched for tesamorelin research in 2025 or 2026, you probably ran into headlines about a "new" tesamorelin. There is one — sort of. In March 2025 the US FDA approved a more concentrated formulation, marketed as EGRIFTA WR, and it became commercially available in September 2025, gradually replacing the older EGRIFTA SV. But read the approval documents and the picture narrows fast: what changed was the vial, the volume and the fridge requirement — not the indication, and not the efficacy evidence. The bridge between old and new was a 36-person pharmacokinetic study in healthy adults.

That distinction matters more than it sounds, because it quietly breaks the one number most people quote when they talk about this peptide: the milligram dose. For background on the compound itself, see our profile at /peptides/tesamorelin.

What is tesamorelin, and what actually changed in 2025?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts one step upstream of growth hormone: rather than supplying GH, it stimulates the pituitary to release its own, which raises IGF-1. It has been FDA-approved since 2010, and only for one thing — reducing excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy.

The 2025 change was a formulation upgrade, internally called F8:

  • Eight times more concentrated than the original 2010 product (F1), and twice as concentrated as EGRIFTA SV (F4).
  • Weekly reconstitution instead of daily. One 11.6 mg vial is mixed with 1.3 mL of diluent and provides seven consecutive daily doses.
  • Room-temperature storage (20–25 °C) before and after reconstitution, for up to 7 days once mixed — no freezing.
  • Less than half the injection volume: 0.16 mL per dose.

Those are real quality-of-life improvements for people on long-term daily therapy. They are not new clinical findings.

The evidence the new vial rests on: 36 healthy adults

The supplemental application was supported by pharmacokinetics, not a fresh efficacy trial. The bridging study — presented as a conference abstract at IDWeek 2025 — was a single-centre, randomised, blinded, two-treatment, two-period, two-sequence crossover in 36 healthy adult participants, each receiving a single dose of each formulation.

Reported geometric least-squares mean ratios were 108.0% for Cmax and 96.9% for AUC0-t, with the 90% confidence interval for AUC0-t falling inside the standard 80–125% bioequivalence window. The authors concluded bioequivalence criteria were met and the concentrated formulation was generally safe and well tolerated.

Worth stating plainly: this is a single-dose Phase 1 crossover, reported so far as a conference abstract rather than a full peer-reviewed paper. It is exactly the right study to answer "does the new vial deliver the same exposure?" It is not designed to answer anything about fat, liver, glucose or long-term safety — and it wasn't meant to.

Why "2 mg of tesamorelin" no longer means one thing

Here is the practical trap. Across three formulations, the labelled daily dose is different every time, because the intended systemic exposure — not the milligram number — is what was held constant:

  • F1 (original EGRIFTA): 2 mg daily, from 1 mg vials.
  • F4 (EGRIFTA SV): 1.4 mg daily, from a 2 mg vial.
  • F8 (EGRIFTA WR): 1.28 mg daily, from an 11.6 mg vial.

So a dose quoted from a 2010–2012 trial paper, a 2019 label and a 2025 label can all describe roughly the same pituitary stimulus while looking like three different doses. Anyone cross-reading old literature against newer product information — or against the mg-per-vial figures printed on unregulated "research" vials that were never bridged to anything — is comparing numbers that aren't interchangeable. Vial strength, reconstitution volume and drawn volume all have to travel together for a dose to mean anything.

The clinical evidence base didn't move — a January 2026 meta-analysis

While the packaging evolved, the underlying dataset stayed where it has been for over a decade. A meta-analysis published in January 2026 in Obesity Research & Clinical Practice searched five databases through July 2025 and found five randomised controlled trials of tesamorelin versus placebo — all in adults with HIV.

Pooled results: visceral adipose tissue fell (mean difference −27.71 cm², 95% CI −38.37 to −17.06), hepatic fat fraction fell by about 4.28 percentage points, lean body mass rose by roughly 1.42 kg, and IGF-1 rose, without serious adverse events or a signal of disturbed glucose control in the pooled analysis.

Read that as confirmation, not expansion. Five trials in one clinical population, with modest sample sizes, cannot tell you what a GHRH analogue does in metabolically healthy adults chasing body composition or "anti-ageing" outcomes — a population that has never been the subject of an adequately powered tesamorelin trial. The compound's most-discussed off-label uses remain extrapolations. Our broader peptides library takes the same line elsewhere: mechanism plus a plausible story is not evidence of benefit.

Tesamorelin Australia: is tesamorelin legal in Australia?

Neither the old nor the new formulation is registered here. Tesamorelin is not on the Australian Register of Therapeutic Goods (ARTG), so there is no Australian-approved tesamorelin product of any concentration. It sits as a prescription-only (Schedule 4) substance, meaning any legitimate human use runs through a doctor and through the TGA's unapproved-goods pathways — Special Access Scheme or Authorised Prescriber — with importation rules applying on top. Supply or possession without authority is an offence, with penalties that vary by state.

The regulatory history elsewhere is also worth knowing: a European marketing application was withdrawn before approval in 2012, so tesamorelin has never been EMA-approved. And for anyone in tested sport, the WADA Prohibited List bans GHRH analogues at all times under class S2 — the new vial changes nothing about that.

One more Australian-relevant footnote: the room-temperature stability of the F8 product is a genuine logistics improvement, and it is often cited approvingly in peptide forums. It does not alter legal status, and it says nothing about the identity, purity or dose accuracy of anything sold outside the regulated supply chain.

What would actually count as new tesamorelin evidence

A useful checklist for the next headline you see:

  • A new indication on a label, not a new vial size.
  • A randomised trial outside HIV, powered for a clinical endpoint — not a PK study, and not a subgroup.
  • Full peer-reviewed publication, not a conference abstract or a company media release.
  • Registry entries with a verifiable, real sponsor. Peptide searches on trial registries turn up demonstration records with invented sponsors; always check who is actually running the study.

The tesamorelin franchise also changed hands commercially in 2025, when an affiliate of Future Pak agreed to acquire Theratechnologies — a deal structured around EGRIFTA gross profit milestones. That is an ownership story, not a research programme, and it gives little reason to expect a new indication push soon.

Want the next verified update on tesamorelin and the wider GHRH class as it lands? Join the free updates list.

FAQ

What is tesamorelin used for?

It is FDA-approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, an indication it has held since 2010. Other widely discussed uses — general fat loss, liver fat in non-HIV populations, cognition, anti-ageing — remain investigational and largely untested in adequately powered trials.

Is tesamorelin legal in Australia?

Tesamorelin is not on the ARTG, so there is no approved Australian product. It is a prescription-only (Schedule 4) substance, and lawful human use requires a doctor working through TGA unapproved-goods pathways such as the Special Access Scheme or Authorised Prescriber.

Is Egrifta WR stronger than Egrifta SV?

No. EGRIFTA WR is more concentrated — eight times the original formulation — but it was approved on the basis of pharmacokinetic bioequivalence, so the intended exposure is the same. That is why its labelled daily dose is 1.28 mg versus 1.4 mg for EGRIFTA SV and 2 mg for the original.

Has tesamorelin been proven to work for weight loss in healthy adults?

Not in trials. The five randomised controlled trials pooled in a January 2026 meta-analysis were all conducted in adults with HIV, and the pooled visceral fat reduction was about 27.7 cm². There is no comparable randomised evidence base in metabolically healthy people.

Sources

This article is information only, not medical advice, and retatrutide.net.au is independent and does not sell or source peptides. Tesamorelin is FDA-approved solely for HIV-associated lipodystrophy, was never EMA-approved (application withdrawn in 2012), and is not on the ARTG in Australia.